Axogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft®

a week ago

ALACHUA, Fla. and TAMPA, Fla., Sept. 06, 2024 ( GLOBE NEWSWIRE ) -- Axogen, Inc. ( NASDAQ: AXGN ) , a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced that it has completed the rolling submission process for its Biologics License ...

Ticker	Sentiment	Impact
AXGN	Neutral	24 %